Targeted probiotic dietary powder for conditioning intestinal microecology and preparation method thereof

Abstract

The invention discloses targeted probiotic dietary powder for conditioning intestinal microecology and a preparation method of the targeted probiotic dietary powder. According to the invention, the micro-ecological health of intestinal tracts is obviously improved through a triple synergistic mechanism. The core probiotic combination directly acts on the key link of intestinal flora imbalance. Lactobacillus plantarum LP-12 inhibits excessive release of intestinal inflammatory factors and alleviates intestinal mucosa damage. The bifidobacterium bifidum TMC3115 enhances tight connection of intestinal epithelial cells and repairs a physical barrier; the Witzia ciliaris MKSWC01 can degrade endotoxin and block the chain reaction of chronic inflammation. Meanwhile, the fucoidin and the galactooligosaccharide are used for accurately feeding the probiotics and enhancing the colonization capability of the probiotics in a colon mucus layer, so that long-acting protection is formed. L-glutamine provides basic nutrition required by intestinal mucosa regeneration, and resistant dextrin continuously generates short-chain fatty acid to maintain a weak acid environment of colon, so that healthy flora ecology is comprehensively reconstructed.

Description

Technical Field

[0001] The present invention belongs to the technical field of health foods, and specifically relates to a targeted probiotic dietary powder for regulating intestinal microecology and a preparation method thereof. Background Art

[0002] Probiotic dietary powder is a dietary supplement that combines probiotics with a variety of nutrients. It comes in powdered form, making it easy to carry and consume. The probiotics in it are living microorganisms that, when consumed in sufficient quantities, can have beneficial effects on the host's health, helping to regulate the balance of intestinal flora, improve digestion, and relieve problems such as constipation and diarrhea. At the same time, dietary powder is also rich in nutrients such as vitamins and minerals, which can provide the body with necessary nourishment. It only needs to be mixed when consumed, and the taste is usually more pleasant. For people with poor intestinal function, weak immunity, or those who are health-conscious, probiotic dietary powder is a convenient, effective and healthy choice that can help maintain the body in good condition.

[0003] However, existing technologies generally have three core defects when regulating intestinal microecology:

[0004] Single strain function: Traditional probiotic products often rely on a single strain or a generic combination, lacking precise compatibility for specific pathologies such as intestinal barrier repair and inflammation suppression, resulting in limited intervention effects;

[0005] Inadequate delivery efficiency: Conventional encapsulation technology cannot effectively resist gastric acid erosion, the survival rate of live bacteria is often less than 20%, and there is a lack of colon-targeted release mechanism, resulting in a large number of probiotics being inactivated in the front of the intestine;

[0006] One-sided repair mechanism: Over-focusing on live bacteria regulation, ignoring direct repair of intestinal mucosa and blocking of inflammatory pathways, unable to resolve systemic inflammation caused by intestinal leakage, and lacking the synergistic effect of synergistic ingredients such as postbiotics. Summary of the Invention

[0007] The purpose of the present invention is to provide a targeted probiotic dietary powder for regulating intestinal microecology and a preparation method thereof in order to solve the above-mentioned problems.

[0008] The technical solution adopted by the present invention is as follows: a targeted probiotic dietary powder for regulating intestinal microecology, the dietary powder comprising:

[0009] Probiotic group:

[0010] Lactobacillus plantarum LP-12: 5 billion CFU;

[0011] Bifidobacterium bifidum TMC3115: 3 billion CFU;

[0012] Weizmannella coagulans MKSWC01: 2 billion CFU;

[0013] Epigenetic tuple:

[0014] Lactobacillus plantarum Lp-299v inactivated metabolites: 200 parts by weight;

[0015] Prebiotics:

[0016] Fucoidan: 600 parts by weight;

[0017] Galacto-oligosaccharide: 400 parts by weight;

[0018] Anti-inflammatory plant group:

[0019] Rosmarinic acid: 50 parts by weight;

[0020] Epigallocatechin: 30 parts by weight;

[0021] Intestinal barrier repair group:

[0022] L-glutamine: 300 parts by weight;

[0023] Sustained-release carrier:

[0024] Resistant dextrin: 1200 parts by weight.

[0025] In a preferred embodiment, a method for preparing a targeted probiotic dietary powder for regulating intestinal microecology comprises the following steps:

[0026] S1: Lactobacillus plantarum LP-12, Bifidobacterium bifidum TMC3115, and Weizmannella coagulans MKSWC01 were fermented and cultured separately, the bacterial sludge was collected by centrifugation, and the live bacteria freeze-dried powder was prepared by freeze-drying process. The live bacteria concentrations were controlled to be 100 billion CFU / g, 60 billion CFU / g, and 40 billion CFU / g, respectively.

[0027] S2: The three bacterial powders from step S1 are mixed with sodium alginate solution, and calcium chloride solution is added dropwise to form gel microspheres; the gel microspheres are then immersed in chitosan solution for coating reinforcement to form sodium alginate-chitosan nanocapsules.

[0028] S3: The nanocapsules are immersed in Eudragit FS30D enteric material solution and spray-dried to form a pH-sensitive enteric coating layer to ensure a gastric acid survival rate of ≥95%.

[0029] S4: centrifuging the fermentation broth of Lactobacillus plantarum Lp-299v, taking the supernatant, concentrating it by ultrafiltration, and spray drying it to prepare an inactivated metabolite powder.

[0030] S5: Weigh according to the formula ratio: 600 parts by weight of fucoidan, 400 parts by weight of galacto-oligosaccharide, 50 parts by weight of rosmarinic acid, 30 parts by weight of epigallocatechin, 300 parts by weight of L-glutamine, and 1200 parts by weight of resistant dextrin, mix with 200 parts by weight of the postbiotic powder in step S4, and ball mill homogenize for 10 minutes.

[0031] S6: Put the coated microcapsules from step S3 and the mixed dry powder from step S5 into a three-dimensional mixer and mix at a low speed for 20 minutes; and pack into aluminum foil bags at a rate of 4 g per bag.

[0032] S7: Random sampling test:

[0033] Total viable bacteria count: ensure ≥10 billion CFU per bag;

[0034] Enteric release rate: verified colon-targeted release > 90%;

[0035] Moisture content: ≤5%.

[0036] S8: The aluminum foil bag is heat-pressed and sealed, the outer packaging is light-proof and moisture-proof, and the production date, batch number and storage conditions are marked.

[0037] In a preferred embodiment, in step S1, Lactobacillus plantarum LP-12 is anaerobically fermented in MRS medium at 37°C for 24 hours, Bifidobacterium bifidum TMC3115 is anaerobically fermented in TPY medium at 37°C for 36 hours, and Weizmannella coagulans MKSWC01 is fermented in modified GAM medium at 37°C for 48 hours. After fermentation, the sludge is collected by centrifugation at 8000 rpm for 15 minutes. The sludge is pre-frozen to -40°C in a freeze dryer for 4 hours, then freeze-dried at -50°C under 0.1 mbar vacuum for 24 hours to produce a live bacteria freeze-dried powder. The live bacteria concentration of the freeze-dried powder is controlled to 100 billion CFU / g for Lactobacillus plantarum LP-12, 60 billion CFU / g for Bifidobacterium bifidum TMC3115, and 40 billion CFU / g for Weizmannella coagulans MKSWC01.

[0038] In a preferred embodiment, in step S2, the three bacterial powders are mixed according to the formula ratio, and a 2% sodium alginate solution is added and stirred thoroughly to form a uniform suspension. The suspension is then added dropwise to a 1.5% calcium chloride solution at a flow rate of 0.5 mL / min using a microinjection pump to form gel microspheres with a diameter of approximately 200 μm. The microspheres are then immersed in a 0.8% chitosan solution and allowed to stand for 20 minutes to form sodium alginate-chitosan bilayer nanocapsules. The microspheres are then rinsed three times with pure water to remove residual reagents.

[0039] In a preferred embodiment, in step S3, the nanocapsules are immersed in 10% Eudragit FS30D enteric material ethanol solution and slowly stirred for 30 minutes to ensure complete infiltration. The microcapsules are taken out and placed in a fluidized bed with an inlet temperature of 40°C and an air volume of 25m 3 The microcapsules were spray-dried at 1000 nm / h to form a pH-sensitive enteric coating layer with a thickness of about 20 μm. The coated microcapsules were cured in a drying oven at 25°C for 12 hours.

[0040] In a preferred embodiment, in step S4, the fermentation broth of Lactobacillus plantarum Lp-299v is centrifuged at 10,000 rpm for 20 minutes to obtain the supernatant, the supernatant is concentrated 5 times by passing through a 10 kDa ultrafiltration membrane, and the concentrate is transferred to a spray drying tower and dried at an inlet temperature of 160°C and an outlet temperature of 70°C to obtain an inactivated metabolite powder, which is then sealed and stored away from light.

[0041] In a preferred embodiment, in step S5, 600 mg of fucoidan, 400 mg of galacto-oligosaccharide, 50 mg of rosmarinic acid, 30 mg of epigallocatechin, 300 mg of L-glutamine, and 1200 mg of resistant dextrin are accurately weighed, and 200 mg of postbiotic powder is added. The mixture is placed in a ball mill and homogenized at 300 rpm for 10 minutes, and then passed through a 100-mesh sieve to ensure uniform powder fineness.

[0042] In a preferred embodiment, in step S6, the coated microcapsules and the mixed dry powder are placed in a three-dimensional mixer and mixed at 15 rpm for 20 minutes. The mixed powder is then filled into aluminum foil bags using an automatic filling machine with a precision of 4.0 g ± 0.1 g per bag, at a filling rate of 30 bags / minute.

[0043] In a preferred embodiment, in step S7, 10 bags are randomly sampled and tested for total viable bacterial count according to GB 4789.35, with a requirement of ≥10 billion CFU per bag. A simulated intestinal fluid release test verifies a colon-targeted release rate >90%. Moisture content is tested using a constant weight method at 105°C, with a standard of ≤5%. All unqualified batches are reprocessed.

[0044] In a preferred embodiment, in step S8, the aluminum foil bags are sealed using a heat press sealer at a temperature of 180°C, a pressure of 0.3 MPa, and a sealing time of 2 seconds. The finished products are then placed in light-proof aluminum foil outer bags, labeled with the product name, batch number, production date, and storage conditions (≤25°C in a cool, dry place). After packaging, the bags are palletized and shipped in a warehouse with a humidity level of <30%.

[0045] In summary, due to the adoption of the above technical solution, the beneficial effects of the present invention are:

[0046] 1. This invention significantly improves intestinal microbiome health through a triple synergistic mechanism. Its core probiotic combination directly targets key areas of intestinal microbial imbalance: Lactobacillus plantarum LP-12 inhibits excessive release of intestinal inflammatory factors, alleviating intestinal mucosal damage; Bifidobacterium bifidum TMC3115 strengthens intestinal epithelial tight junctions, repairing the physical barrier; and Weizmannia coagulans MKSWC01 degrades endotoxins, blocking the chronic inflammatory chain reaction. Simultaneously, fucoidan and galacto-oligosaccharides precisely nourish the probiotics and enhance their colonization in the colonic mucus layer, providing long-lasting protection. Postbiotic components directly activate intestinal epithelial repair signals, accelerating mucosal healing. Rosmarinic acid and epigallocatechin-3-glucose dually inhibit inflammatory pathways, reducing tissue damage caused by immune overactivation. L-glutamine provides essential nutrients for intestinal mucosal regeneration, while resistant dextrins continuously produce short-chain fatty acids to maintain a mildly acidic environment in the colon, comprehensively reconstructing a healthy microbial ecosystem.

[0047] 2. The present invention can significantly improve the bloating, diarrhea or constipation problems of patients with irritable bowel syndrome in the short term, and alleviate digestive discomfort caused by antibiotic-related flora disturbances; long-term use can repair systemic low-grade inflammation caused by chronic intestinal leakage and reduce the risk of toxins entering the blood. For people with weakened immunity, it can enhance intestinal sIgA secretion and immune cell activity to improve anti-infection ability; for those with metabolic abnormalities, it can synergistically regulate glycolipid metabolism and uric acid excretion pathways. Its colon-targeted release technology ensures efficient colonization of live bacteria, and the 14-day cycle design matches the renewal rules of intestinal flora, achieving a transformation from symptom control to reconstruction of microecological homeostasis, providing a safe and fundamental solution for all types of intestinal sub-health people. BRIEF DESCRIPTION OF THE DRAWINGS

[0048] Figure 1 It is a schematic diagram of the process principle of the present invention. DETAILED DESCRIPTION

[0049] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the present invention will be further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.

[0050] Example:

[0051] Reference Figure 1 , a targeted probiotic dietary powder for regulating intestinal microecology and a preparation method thereof, the dietary powder comprising:

[0052] Probiotic group:

[0053] Lactobacillus plantarum LP-12: 5 billion CFU (lipid-lowering strain, reduces intestinal inflammation);

[0054] Bifidobacterium bifidum TMC3115: 3 billion CFU (enhances intestinal barrier integrity);

[0055] Weizmannella coagulans MKSWC01: 2 billion CFU (endotoxin-degrading);

[0056] Epigenetic tuple:

[0057] Inactivated metabolite of Lactobacillus plantarum Lp-299v: 200 parts by weight (directly repairs intestinal epithelial tight junction protein ZO-1);

[0058] Prebiotics:

[0059] Fucoidan: 600 parts by weight (targeted to enhance probiotic colonization of the colonic mucus layer);

[0060] Galacto-oligosaccharide: 400 parts by weight (promotes the proliferation of bifidobacteria);

[0061] Anti-inflammatory plant group:

[0062] Rosmarinic acid: 50 parts by weight (inhibits IL-6 / IL-1β inflammatory factors);

[0063] Epigallocatechin: 30 parts by weight (blocks NF-κB pathway);

[0064] S3: Enteric coating

[0065] The nanocapsules are immersed in Eudragit FS30D enteric material solution and spray-dried to form a pH-sensitive enteric coating layer, ensuring a gastric acid survival rate of ≥95%.

[0066] S4: Postbiotic Preparation

[0067] The fermentation broth of Lactobacillus plantarum Lp-299v was centrifuged, and the supernatant was concentrated by ultrafiltration and spray-dried to prepare an inactivated metabolite powder (postbiotic).

[0068] S5: Dry powder mixing

[0069] According to the formula ratio, 600 parts by weight of fucoidan, 400 parts by weight of galacto-oligosaccharide, 50 parts by weight of rosmarinic acid, 30 parts by weight of epigallocatechin, 300 parts by weight of L-glutamine, and 1200 parts by weight of resistant dextrin were weighed and mixed with 200 parts by weight of the postbiotic powder from step S4, and ball milled for homogenization for 10 minutes.

[0070] S6: Mixing and packaging

[0071] The coated microcapsules from step S3 and the mixed dry powder from step S5 were placed in a three-dimensional mixer and mixed at a low speed for 20 minutes; the mixture was then packaged into aluminum foil bags at a rate of 4 g per bag.

[0072] S7: Quality Control

[0073] Random sampling inspection:

[0074] Total viable bacteria count (GB 4789.35): Ensure that each bag contains ≥10 billion CFU;

[0075] Enteric release rate (simulated intestinal fluid): verified colon-targeted release > 90%;

[0076] Moisture content (GB 5009.3): ≤5%.

[0077] S8: Sealed packaging

[0078] The aluminum foil bag is heat-pressed and sealed, the outer packaging is light-proof and moisture-proof, and is marked with the production date, batch number and storage conditions (in a cool and dry place, ≤25℃).

[0079] In step S1, Lactobacillus plantarum LP-12 was anaerobically fermented in MRS medium at 37°C for 24 hours, Bifidobacterium bifidum TMC3115 was anaerobically fermented in TPY medium at 37°C for 36 hours, and Weizmannella coagulans MKSWC01 was fermented in modified GAM medium at 37°C for 48 hours. After fermentation, the sludge was collected by centrifugation at 8000 rpm for 15 minutes. The sludge was pre-frozen to -40°C in a freeze dryer for 4 hours and then freeze-dried at -50°C under 0.1 mbar vacuum conditions for 24 hours to produce a freeze-dried powder of live bacteria. The live bacteria concentration of the freeze-dried powder of Lactobacillus plantarum LP-12 was controlled to 100 billion CFU / g, Bifidobacterium bifidum TMC3115 to 60 billion CFU / g, and Weizmannella coagulans MKSWC01 to 40 billion CFU / g.

[0080] In step S2, the three bacterial powders are mixed according to the formula ratio, and a 2% sodium alginate solution is added and stirred thoroughly to form a uniform suspension. Using a microsyringe pump, the suspension is dripped into a 1.5% calcium chloride solution at a flow rate of 0.5 mL / min to form gel microspheres with a diameter of approximately 200 μm. The microspheres are then immersed in a 0.8% chitosan solution and allowed to stand for 20 minutes to form sodium alginate-chitosan bilayer nanocapsules. The microspheres are then rinsed three times with pure water to remove any residual reagents.

[0081] In step S3, the nanocapsules were immersed in 10% Eudragit FS30D enteric material ethanol solution and stirred slowly for 30 minutes to ensure complete infiltration. The microcapsules were taken out and placed in a fluidized bed with an inlet temperature of 40°C and an air volume of 25m 3 The microcapsules were spray-dried at 1000 nm / h to form a pH-sensitive enteric coating layer with a thickness of about 20 μm. The coated microcapsules were cured in a drying oven at 25°C for 12 hours.

[0082] In step S4, the fermentation broth of Lactobacillus plantarum Lp-299v was centrifuged at 10,000 rpm for 20 minutes to obtain the supernatant, the supernatant was concentrated 5 times by passing through a 10 kDa ultrafiltration membrane, and the concentrate was transferred to a spray drying tower and dried at an inlet temperature of 160° C. and an outlet temperature of 70° C. to obtain an inactivated metabolite powder, which was sealed and stored away from light.

[0083] In step S5, 600 mg of fucoidan, 400 mg of galacto-oligosaccharide, 50 mg of rosmarinic acid, 30 mg of epigallocatechin, 300 mg of L-glutamine, and 1200 mg of resistant dextrin were accurately weighed, and 200 mg of postbiotic powder was added. The mixture was placed in a ball mill and homogenized at 300 rpm for 10 minutes. The powder was then passed through a 100-mesh sieve to ensure uniform fineness.

[0084] In step S6, the coated microcapsules and the mixed dry powder were placed in a three-dimensional mixer and mixed at 15 rpm for 20 minutes. The mixed powder was filled into aluminum foil bags by an automatic filling machine with a precision of 4.0 g ± 0.1 g per bag, and the filling speed was controlled at 30 bags / minute.

[0085] In step S7, 10 bags are randomly sampled and tested for total viable bacterial count according to GB 4789.35, with a requirement of ≥10 billion CFU per bag. A simulated intestinal fluid release test verifies a colon-targeted release rate >90%. Moisture content is tested using the 105°C constant weight method, with a standard of ≤5%. All unqualified batches are reprocessed.

[0086] In step S8, the aluminum foil bags are sealed using a heat-sealing machine at a temperature of 180°C, a pressure of 0.3 MPa, and a sealing time of 2 seconds. The finished products are then placed in light-proof aluminum foil outer bags and labeled with the product name, batch number, production date, and storage requirements in a cool, dry place (≤25°C). After packaging, the products are palletized and shipped in a warehouse with a humidity level below 30%.

[0087] From the above, it can be seen that the present invention significantly improves intestinal microbiome health through a triple synergistic mechanism. Its core probiotic combination directly targets key areas of intestinal microbial imbalance: Lactobacillus plantarum LP-12 inhibits excessive release of intestinal inflammatory factors, alleviating intestinal mucosal damage; Bifidobacterium bifidum TMC3115 strengthens intestinal epithelial tight junctions, repairing the physical barrier; and Weizmannia coagulans MKSWC01 degrades endotoxins, interrupting the chronic inflammatory chain reaction. Simultaneously, fucoidan and galacto-oligosaccharides precisely nourish the probiotics and enhance their colonization in the colonic mucus layer, providing long-lasting protection. Postbiotic components directly activate intestinal epithelial repair signals, accelerating mucosal healing. Rosmarinic acid and epigallocatechin-3-glucose dually inhibit inflammatory pathways, reducing tissue damage caused by immune overactivation. L-glutamine provides essential nutrients for intestinal mucosal regeneration, while resistant dextrin continuously produces short-chain fatty acids to maintain a mildly acidic environment in the colon, comprehensively reconstructing a healthy microbial ecosystem.

[0088] In the present invention, in the short term, it can significantly improve the abdominal distension, diarrhea or constipation problems of patients with irritable bowel syndrome, and alleviate digestive discomfort caused by antibiotic-related flora disturbances; long-term use can repair systemic low-grade inflammation caused by chronic intestinal leakage and reduce the risk of toxins entering the blood. For people with low immunity, it improves anti-infection ability by enhancing intestinal sIgA secretion and immune cell activity; for those with metabolic abnormalities, it synergistically regulates glycolipid metabolism and uric acid excretion pathways. Its colon-targeted release technology ensures efficient colonization of live bacteria, and the 14-day cycle design matches the renewal rules of intestinal flora, realizing the transformation from symptom control to reconstruction of microecological homeostasis, providing a safe and fundamental solution for all types of intestinal sub-health people.

[0089] It should be noted that, in this document, relational terms such as first and second, etc., are used only to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any actual relationship or order between these entities or operations. Moreover, the term "comprises" or any other variant thereof is intended to cover non-exclusive inclusion, so that a process, method, article or device that includes a series of elements includes not only those elements, but also other elements that are not explicitly listed, or also includes elements that are inherent to such process, method, article or device. In the absence of further restrictions, an element defined by the sentence "comprises a ..." does not exclude the presence of other identical elements in the process, method, article or device that includes the element.

[0090] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the various embodiments of the present invention.

Claims

1. A targeted probiotic dietary powder for regulating intestinal microecology, characterized by: The dietary powder comprises: Probiotic group: Lactobacillus plantarum LP-12: 5 billion CFU; Bifidobacterium bifidum TMC3115: 3 billion CFU; Weizmannella coagulans MKSWC01: 2 billion CFU; Epigenetic tuple: Lactobacillus plantarum Lp-299v inactivated metabolites: 200 parts by weight; Prebiotics: Fucoidan: 600 parts by weight; Galacto-oligosaccharide: 400 parts by weight; Anti-inflammatory plant group: Rosmarinic acid: 50 parts by weight; Epigallocatechin: 30 parts by weight; Intestinal barrier repair group: L-glutamine: 300 parts by weight; Sustained-release carrier: Resistant dextrin: 1200 parts by weight.

2. The method for preparing a targeted probiotic dietary powder for regulating intestinal microecology according to claim 1, characterized in that: The method comprises the following steps: S1: Lactobacillus plantarum LP-12, Bifidobacterium bifidum TMC3115, and Weizmannella coagulans MKSWC01 were fermented and cultured separately, the bacterial sludge was collected by centrifugation, and the live bacteria freeze-dried powder was prepared by freeze-drying process. The live bacteria concentrations were controlled to be 100 billion CFU / g, 60 billion CFU / g, and 40 billion CFU / g, respectively; S2: Take the three bacterial powders from step S1, mix them with sodium alginate solution, and add calcium chloride solution to form gel microspheres; then immerse them in chitosan solution for coating reinforcement to form sodium alginate-chitosan nanocapsules; S3: The nanocapsules are immersed in Eudragit FS30D enteric material solution and spray-dried to form a pH-sensitive enteric coating layer, ensuring a gastric acid survival rate of ≥95%; S4: centrifuging the Lactobacillus plantarum Lp-299v fermentation broth, concentrating the supernatant by ultrafiltration, and spray drying to prepare an inactivated metabolite powder; S5: According to the formula ratio, weigh 600 parts by weight of fucoidan, 400 parts by weight of galacto-oligosaccharide, 50 parts by weight of rosmarinic acid, 30 parts by weight of epigallocatechin, 300 parts by weight of L-glutamine, and 1200 parts by weight of resistant dextrin, mix with 200 parts by weight of the postbiotic powder in step S4, and ball mill homogenize for 10 minutes; S6: Place the coated microcapsules from step S3 and the mixed dry powder from step S5 into a three-dimensional mixer and mix at low speed for 20 minutes; then pack into aluminum foil bags at a rate of 4 g per bag; S7: Random sampling test: Total viable bacteria count: ensure ≥10 billion CFU per bag; Enteric release rate: verified colon-targeted release > 90%; Moisture content: ≤5%; S8: The aluminum foil bag is heat-pressed and sealed, the outer packaging is light-proof and moisture-proof, and the production date, batch number and storage conditions are marked.

3. The method for preparing a targeted probiotic dietary powder for regulating intestinal microecology according to claim 1, characterized in that: In the step S1, Lactobacillus plantarum LP-12 is anaerobically fermented in MRS medium at 37° C. for 24 hours, Bifidobacterium bifidum TMC3115 is anaerobically fermented in TPY medium at 37° C. for 36 hours, and Weizmannella coagulans MKSWC01 is fermented in modified GAM medium at 37° C. for 48 hours; after the fermentation is completed, the bacterial sludge is collected by centrifugation at 8000 rpm for 15 minutes, and the bacterial sludge is pre-frozen to -40° C. in a freeze dryer for 4 hours, and then freeze-dried at -50° C. and 0.1 mbar vacuum conditions for 24 hours to prepare a live bacteria freeze-dried powder; the live bacteria concentration of the Lactobacillus plantarum LP-12 freeze-dried powder is controlled to be 100 billion CFU / g, 60 billion CFU / g for Bifidobacterium bifidum TMC3115, and 40 billion CFU / g for Weizmannella coagulans MKSWC01.

4. The method for preparing a targeted probiotic dietary powder for regulating intestinal microecology according to claim 1, wherein: In step S2, the three bacterial powders are mixed according to the formula ratio, 2% sodium alginate solution is added and stirred thoroughly to form a uniform suspension; the suspension is dripped into a 1.5% calcium chloride solution at a flow rate of 0.5 mL / min using a microinjection pump to form gel microspheres with a diameter of about 200 μm; the microspheres are immersed in a 0.8% chitosan solution and allowed to stand for 20 minutes to form sodium alginate-chitosan double-layer nanocapsules, and the residual reagents are rinsed three times with pure water.

5. The method for preparing a targeted probiotic dietary powder for regulating intestinal microecology according to claim 1, characterized in that: In step S3, the nanocapsules were immersed in 10% Eudragit FS30D enteric material ethanol solution and stirred slowly for 30 minutes to ensure complete infiltration; the microcapsules were taken out and placed in a fluidized bed with an inlet temperature of 40°C and an air volume of 25m 3 / h to form a pH-sensitive enteric coating layer with a thickness of about 20 μm; after coating, the microcapsules were cured in a drying oven at 25°C for 12 hours.

6. The method for preparing a targeted probiotic dietary powder for regulating intestinal microecology according to claim 1, characterized in that: In step S4, the fermentation broth of Lactobacillus plantarum Lp-299v is centrifuged at 10,000 rpm for 20 minutes to obtain the supernatant, the supernatant is concentrated 5 times by passing through a 10 kDa ultrafiltration membrane, and the concentrate is transferred to a spray drying tower and dried under conditions of an inlet temperature of 160° C. and an outlet temperature of 70° C. to obtain an inactivated metabolite powder, which is then sealed and stored away from light.

7. The method for preparing a targeted probiotic dietary powder for regulating intestinal microecology according to claim 1, characterized in that: In step S5, 600 mg of fucoidan, 400 mg of galacto-oligosaccharide, 50 mg of rosmarinic acid, 30 mg of epigallocatechin, 300 mg of L-glutamine, and 1200 mg of resistant dextrin were accurately weighed, and 200 mg of postbiotic powder was added; the mixture was placed in a ball mill, ball-milled at 300 rpm for 10 minutes, and passed through a 100-mesh sieve to ensure uniform powder fineness.

8. The method for preparing a targeted probiotic dietary powder for regulating intestinal microecology according to claim 1, characterized in that: In step S6, the coated microcapsules and the mixed dry powder are put into a three-dimensional mixer and mixed at a speed of 15 rpm for 20 minutes; the mixed powder is filled into aluminum foil bags by an automatic filling machine with a precision of 4.0 g ± 0.1 g per bag, and the filling speed is controlled to 30 bags / minute.

9. The method for preparing a targeted probiotic dietary powder for regulating intestinal microecology according to claim 1, characterized in that: In step S7, 10 bags of samples are randomly selected and tested for total viable bacteria according to GB 4789.35, requiring ≥10 billion CFU per bag; a simulated intestinal fluid release experiment verifies that the colon-targeted release rate is >90%; the moisture content is tested using the 105°C constant weight method, with a standard of ≤5%; all unqualified batches are reworked.

10. The method for preparing a targeted probiotic dietary powder for regulating intestinal microecology according to claim 1, characterized in that: In step S8, the aluminum foil bag is sealed by a hot press sealing machine at a sealing temperature of 180° C., a pressure of 0.3 MPa, and a sealing time of 2 seconds; The finished products are packed into light-proof aluminum film outer bags, marked with product name, batch number, production date and storage conditions in a cool and dry place ≤25℃; after packing, they are palletized and stored in a warehouse with humidity <30%.

Images